Lupin Recalls Bekyree Tablets Due to Content Uniformity Failures
Lupin Pharmaceuticals is recalling specific lots of Bekyree oral contraceptives because they failed content and blend uniformity tests.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which indicates the product is unlikely to cause adverse health consequences. The issue is a manufacturing specification failure (content uniformity) without reported injuries or illnesses.
Plain-English summary
Lupin Pharmaceuticals Inc. is voluntarily recalling 1,712 cartons of Bekyree (desogestrel and ethinyl estradiol tablets USP, 0.15 mg/0.02 mg and ethinyl estradiol tablets USP, 0.01 mg). The affected product is packaged in 1 Wallet of 28 Tablets (NDC 68180-879-11) or 3 Wallets of 28 Tablets Each per carton (NDC 68180-879-13). The specific lot number is L800915, with an expiration date of July 2020.
The recall was initiated because the product failed Content Uniformity Specifications, specifically showing out-of-specification test results for content and blend uniformity. This means the tablets may not contain the intended amount of active ingredients in a consistent manner.
The affected product was distributed nationwide in the USA and Puerto Rico. Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider for guidance on alternative contraception. The product is prescription-only.
The recalled product
- Product
- Bekyree (desogestrel and ethinyl estradiol tablets USP, 0.15 mg/0.02 mg and ethinyl estradiol tablets USP, 0.01 mg), packaged in 1 Wallet of 28 Tablets (NDC 68180-879-11), 3 Wallets of 28 Tablets Each per carton (NDC 68180-879-13), Rx Only, Distributed by: Lupin Pharmaceuticals,
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Category
- Drug — Oral Contraceptive
- Affected units
- 1,712
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: L800915
- Exp July 2020
Distribution
Part of a larger recall action
This product is one of 2 recalled by Lupin Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateSertraline tablets recalled because bottle seals are not adhering
FDA (Drugs) · 2025-12-17
Same hazard · content uniformity
See all →- HighOral contraceptive tablets recalled after failing content uniformity specifications
FDA (Drugs) · 2025-10-15
- HighCefixime Oral Suspension Recalled for Failed Content Uniformity Specifications
FDA (Drugs) · 2024-06-26
- SevereFDA Recalls Phenytoin Oral Suspension Due to Content Uniformity Failure
FDA (Drugs) · 2023-12-27
- ModerateDofetilide Capsules Recalled Due to Out-of-Specification Content Uniformity
FDA (Drugs) · 2023-08-16
- ModerateDofetilide Capsules Recalled for Failed Content Uniformity Specifications
FDA (Drugs) · 2023-03-29